Reported Saturday, Beam Therapeutics Highlights Risto-Cel Durable Hemoglobin F Induction >60% And Hemoglobin S Reduction <40% With Resolution Of Anemia Up To 20 Months

Benzinga · 2d ago
  • Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Durable for up to 20 Months
  • Patients Required a Median of One Cell Collection Cycle and Experienced Rapid Neutrophil and Platelet Engraftment
  • Safety Profile Remained Consistent with Busulfan Conditioning, Autologous Hematopoietic Stem Cell Transplantation and Underlying SCD